| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glomerulosclerosis, Focal Segmental | 4 | 2023 | 43 | 1.920 |
Why?
|
| Kidney Transplantation | 8 | 2022 | 839 | 1.810 |
Why?
|
| Blood Component Removal | 2 | 2022 | 19 | 1.590 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 61 | 1.520 |
Why?
|
| Acute Kidney Injury | 6 | 2022 | 232 | 1.490 |
Why?
|
| Graft Rejection | 6 | 2021 | 458 | 1.220 |
Why?
|
| Kidney Diseases | 3 | 2022 | 307 | 0.930 |
Why?
|
| Renal Insufficiency | 4 | 2022 | 121 | 0.920 |
Why?
|
| Hydronephrosis | 1 | 2022 | 12 | 0.820 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2019 | 12 | 0.820 |
Why?
|
| Urinary Tract | 1 | 2022 | 10 | 0.820 |
Why?
|
| Immunosuppressive Agents | 5 | 2019 | 514 | 0.800 |
Why?
|
| Child | 22 | 2022 | 6405 | 0.770 |
Why?
|
| Kidney Tubules, Proximal | 5 | 2012 | 81 | 0.740 |
Why?
|
| Sodium-Hydrogen Exchangers | 4 | 2012 | 43 | 0.670 |
Why?
|
| Fish Oils | 1 | 2019 | 21 | 0.660 |
Why?
|
| Kidney | 4 | 2022 | 945 | 0.610 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.610 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 186 | 0.590 |
Why?
|
| Aftercare | 1 | 2018 | 114 | 0.570 |
Why?
|
| Infant, Newborn | 10 | 2022 | 2455 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 33 | 0.520 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 33 | 0.520 |
Why?
|
| Dexamethasone | 2 | 2012 | 150 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 504 | 0.440 |
Why?
|
| Retrospective Studies | 15 | 2022 | 7277 | 0.430 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2019 | 123 | 0.420 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2012 | 37 | 0.410 |
Why?
|
| Central Nervous System Diseases | 1 | 2012 | 40 | 0.410 |
Why?
|
| Methotrexate | 1 | 2012 | 91 | 0.400 |
Why?
|
| Immunologic Factors | 1 | 2012 | 87 | 0.390 |
Why?
|
| Acidosis | 2 | 2012 | 31 | 0.390 |
Why?
|
| Nephrology | 2 | 2022 | 43 | 0.390 |
Why?
|
| Humans | 33 | 2023 | 68618 | 0.380 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 36 | 0.380 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2022 | 38 | 0.380 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 649 | 0.360 |
Why?
|
| Adolescent | 13 | 2022 | 8912 | 0.350 |
Why?
|
| Biopsy | 5 | 2019 | 540 | 0.340 |
Why?
|
| Infant | 11 | 2022 | 2891 | 0.340 |
Why?
|
| Treatment Outcome | 10 | 2020 | 7029 | 0.320 |
Why?
|
| Male | 21 | 2022 | 37321 | 0.310 |
Why?
|
| Renal Replacement Therapy | 2 | 2017 | 40 | 0.290 |
Why?
|
| Female | 21 | 2022 | 38074 | 0.290 |
Why?
|
| Fetus | 2 | 2022 | 157 | 0.280 |
Why?
|
| Diarrhea | 2 | 2020 | 63 | 0.280 |
Why?
|
| Recurrence | 2 | 2022 | 948 | 0.270 |
Why?
|
| Child, Preschool | 8 | 2022 | 3187 | 0.260 |
Why?
|
| Hypertension | 3 | 2022 | 1535 | 0.260 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2021 | 113 | 0.250 |
Why?
|
| Bortezomib | 2 | 2017 | 45 | 0.250 |
Why?
|
| Rituximab | 3 | 2017 | 61 | 0.240 |
Why?
|
| Creatinine | 2 | 2022 | 243 | 0.220 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2022 | 15 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2022 | 18 | 0.210 |
Why?
|
| Dilatation, Pathologic | 1 | 2022 | 58 | 0.200 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 89 | 0.200 |
Why?
|
| Dilatation | 1 | 2022 | 58 | 0.200 |
Why?
|
| Pseudohypoaldosteronism | 1 | 2021 | 4 | 0.200 |
Why?
|
| Sclerosis | 1 | 2021 | 32 | 0.200 |
Why?
|
| Hyponatremia | 1 | 2021 | 20 | 0.190 |
Why?
|
| Remission Induction | 1 | 2021 | 111 | 0.190 |
Why?
|
| Microvilli | 5 | 2012 | 22 | 0.190 |
Why?
|
| Drug Resistance | 1 | 2021 | 223 | 0.180 |
Why?
|
| Nephrectomy | 1 | 2021 | 103 | 0.180 |
Why?
|
| Critical Illness | 2 | 2022 | 191 | 0.180 |
Why?
|
| Lupus Nephritis | 1 | 2022 | 193 | 0.180 |
Why?
|
| Fibroblast Growth Factors | 2 | 2011 | 51 | 0.180 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2021 | 138 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 123 | 0.170 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 343 | 0.170 |
Why?
|
| Incidence | 3 | 2021 | 1603 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.170 |
Why?
|
| Heart Failure | 2 | 2019 | 1180 | 0.170 |
Why?
|
| Nephrosis, Lipoid | 1 | 2018 | 9 | 0.160 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2018 | 8 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1140 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 378 | 0.160 |
Why?
|
| Albuminuria | 1 | 2019 | 171 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 468 | 0.150 |
Why?
|
| Pregnancy | 2 | 2022 | 2334 | 0.150 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2012 | 618 | 0.150 |
Why?
|
| Parenteral Nutrition | 1 | 2017 | 39 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 8 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 11 | 0.150 |
Why?
|
| Sodium-Hydrogen Exchanger 3 | 3 | 2012 | 6 | 0.140 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2017 | 5 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2017 | 52 | 0.140 |
Why?
|
| Hepatitis | 1 | 2017 | 25 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 341 | 0.140 |
Why?
|
| Hepatitis B | 1 | 2017 | 42 | 0.140 |
Why?
|
| Risk Factors | 5 | 2023 | 5731 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2017 | 30 | 0.140 |
Why?
|
| Echocardiography | 1 | 2019 | 515 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2019 | 705 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2019 | 384 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.140 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2017 | 174 | 0.130 |
Why?
|
| Antibodies | 1 | 2017 | 241 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2019 | 706 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 365 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 189 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 364 | 0.130 |
Why?
|
| Prognosis | 3 | 2018 | 2093 | 0.130 |
Why?
|
| ROC Curve | 1 | 2015 | 392 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2017 | 329 | 0.120 |
Why?
|
| Bicarbonates | 2 | 2012 | 21 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 2 | 2011 | 2 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2011 | 6 | 0.120 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2013 | 3 | 0.110 |
Why?
|
| Midwestern United States | 3 | 2019 | 36 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2017 | 328 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2013 | 18 | 0.110 |
Why?
|
| Calcitriol | 2 | 2011 | 106 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2013 | 40 | 0.110 |
Why?
|
| Pyrazines | 1 | 2013 | 46 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2013 | 82 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2018 | 2007 | 0.110 |
Why?
|
| Kidney Calculi | 1 | 2013 | 19 | 0.110 |
Why?
|
| Hypotension | 1 | 2013 | 74 | 0.110 |
Why?
|
| Algorithms | 2 | 2015 | 1196 | 0.110 |
Why?
|
| Fructose | 1 | 2013 | 51 | 0.110 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 8 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 30 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 24 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2011 | 1664 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 164 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 335 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2022 | 1451 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1753 | 0.100 |
Why?
|
| Sodium | 1 | 2011 | 161 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2013 | 223 | 0.090 |
Why?
|
| Time Factors | 3 | 2019 | 4655 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 208 | 0.090 |
Why?
|
| Vancomycin | 1 | 2011 | 60 | 0.090 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 4 | 0.090 |
Why?
|
| Aminoglycosides | 1 | 2011 | 54 | 0.090 |
Why?
|
| Amiloride | 1 | 2010 | 22 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2013 | 402 | 0.090 |
Why?
|
| Graft Survival | 1 | 2013 | 465 | 0.090 |
Why?
|
| Young Adult | 5 | 2022 | 5717 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 155 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 202 | 0.090 |
Why?
|
| Seizures | 1 | 2012 | 279 | 0.090 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2009 | 1 | 0.090 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2009 | 1 | 0.090 |
Why?
|
| Adult | 6 | 2022 | 21403 | 0.090 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2009 | 11 | 0.090 |
Why?
|
| Hypophosphatemia | 1 | 2009 | 6 | 0.080 |
Why?
|
| United States | 2 | 2021 | 7367 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2010 | 396 | 0.080 |
Why?
|
| Phosphorus | 1 | 2009 | 64 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 166 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 189 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 154 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 240 | 0.080 |
Why?
|
| Mice | 5 | 2012 | 8474 | 0.080 |
Why?
|
| Epilepsy | 1 | 2013 | 336 | 0.080 |
Why?
|
| Rats | 3 | 2011 | 5300 | 0.080 |
Why?
|
| Contrast Media | 1 | 2011 | 595 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 274 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 2791 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2022 | 3705 | 0.070 |
Why?
|
| Animals | 7 | 2012 | 20881 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 1038 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1293 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1615 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1465 | 0.060 |
Why?
|
| Intestinal Mucosa | 2 | 2017 | 219 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 2223 | 0.050 |
Why?
|
| Apolipoprotein L1 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1864 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2023 | 51 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2550 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2012 | 1692 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 127 | 0.050 |
Why?
|
| Pediatricians | 1 | 2021 | 9 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2022 | 152 | 0.050 |
Why?
|
| Failure to Thrive | 1 | 2021 | 17 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 39 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2022 | 155 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 63 | 0.050 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2020 | 6 | 0.050 |
Why?
|
| Cryptosporidiosis | 1 | 2020 | 7 | 0.050 |
Why?
|
| Cryptosporidium | 1 | 2020 | 9 | 0.050 |
Why?
|
| Sapovirus | 1 | 2020 | 7 | 0.050 |
Why?
|
| Genotype | 1 | 2023 | 786 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 652 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 88 | 0.040 |
Why?
|
| Norovirus | 1 | 2020 | 31 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 467 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 492 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2020 | 110 | 0.040 |
Why?
|
| Birth Weight | 1 | 2019 | 186 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 389 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 77 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 191 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 867 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 245 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2017 | 51 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2017 | 59 | 0.040 |
Why?
|
| Seroconversion | 1 | 2017 | 3 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 8 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 17 | 0.040 |
Why?
|
| Thymectomy | 1 | 2017 | 11 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 521 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2358 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.040 |
Why?
|
| Immune System | 1 | 2017 | 63 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 112 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 94 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 780 | 0.030 |
Why?
|
| Sirolimus | 1 | 2017 | 118 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 703 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1174 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2017 | 127 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 536 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 850 | 0.030 |
Why?
|
| Lung | 1 | 2019 | 849 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 682 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 109 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2077 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 255 | 0.030 |
Why?
|
| Hypercalciuria | 1 | 2013 | 1 | 0.030 |
Why?
|
| Alkalies | 1 | 2013 | 6 | 0.030 |
Why?
|
| Citric Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1851 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 597 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.030 |
Why?
|
| Models, Animal | 1 | 2012 | 252 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1593 | 0.020 |
Why?
|
| Phosphates | 1 | 2011 | 72 | 0.020 |
Why?
|
| Homeostasis | 1 | 2012 | 291 | 0.020 |
Why?
|
| South Carolina | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Metyrapone | 1 | 2010 | 3 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 581 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 89 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 978 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1447 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 117 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1619 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 447 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 1752 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2673 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2083 | 0.020 |
Why?
|
| Middle Aged | 1 | 2018 | 21147 | 0.010 |
Why?
|